178906-01-9Relevant academic research and scientific papers
Synthesis of E-selectin inhibitors: Use of an aryl-cyclohexyl ether as a disaccharide scaffold
Liu, Aijun,Dillon, Kathleen,Campbell, Robert M.,Cox, Don C.,Huryn, Donna M.
, p. 3785 - 3788 (1996)
A series of potential E-selectin antagonists were designed and synthesized based on the bound conformation of sLe(x), as well as the functional group requirements for anti-adhesion activity. A non carbohydrate scaffolding using an aryl-cyclohexyl ether which can orient the critical acid and fucose residues in appropriate positions has been investigated. The inhibitory activity of members of this series suggests the feasibility of non- carbohydrate E-selectin antagonists.
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
-
, (2019/03/05)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
Macrocyclic MCL-1 inhibitors and methods of use
-
, (2019/02/28)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
-
, (2019/03/05)
The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
